Complimentary Technical Snapshots on Adverum Biotechnologies and Three More Biotech Stocks

Stock Research Monitor: ADAP, ADRO, and ADXS

LONDON, UK / ACCESSWIRE / June 7, 2018 / If you want a free Stock Review on ADVM sign up now at www.wallstequities.com/registration. Featured today on WallStEquities.com is the Biotechnology industry, which focuses on novel drug development and clinical research aimed at treating diseases and medical conditions. Under evaluation this morning are four equities: Adaptimmune Therapeutics PLC (NASDAQ: ADAP), Aduro BioTech Inc. (NASDAQ: ADRO), Advaxis Inc. (NASDAQ: ADXS), and Adverum Biotechnologies Inc. (NASDAQ: ADVM). All you have to do is sign up today for this free limited time offer by clicking the link below.

www.wallstequities.com/registration

Adaptimmune Therapeutics

Shares in Abingdon, the UK headquartered Adaptimmune Therapeutics PLC climbed 1.91%, ending Wednesday’s trading session at $12.83. The stock recorded a trading volume of 561,990 shares. The Company’s shares have surged 60.37% over the last three months and 151.08% over the past year. The stock is trading 3.83% and 41.56% above its 50-day and 200-day moving averages, respectively. Moreover, shares of Adaptimmune Therapeutics, which focuses on the provision of cancer immunotherapy products based on its proprietary Specific Peptide Enhanced Affinity Receptor T-cell platform, have a Relative Strength Index (RSI) of 53.09.

On June 04th, 2018, Adaptimmune Therapeutics announced that the independent safety review committee has recommended dose escalation in the MAGE-A4 basket study, based on an acceptable safety profile in three patients dosed with 100 million cells. The company will start treating patients with the target dose of one billion transduced MAGE-A4 SPEAR T-cells in the ongoing basket study. Get the full research report on ADAP for free by clicking below at:

www.wallstequities.com/registration/?symbol=ADAP

Aduro BioTech

Berkeley, California-based Aduro BioTech Inc.’s stock declined 2.94%, closing the day at $6.60 with a total trading volume of 497,529 shares. The stock is trading 16.30% below their 50-day moving average. Shares of the Company, which focuses on the discovery, development, and commercialization of therapies that transform the treatment of challenging diseases, have an RSI of 31.26. Access the free research report on ADRO now by signing up at:

www.wallstequities.com/registration/?symbol=ADRO

Advaxis

On Wednesday, shares in Princeton, New Jersey-based Advaxis Inc. recorded a trading volume of 537,827 shares. The stock ended the day 2.40% higher at $1.71. The Company’s shares have advanced 1.79% in the past month. The stock is trading below its 50-day moving average by 1.97%. Furthermore, shares of Advaxis, which focuses on the discovery, development, and commercialization of Listeria monocytogenes technology-based immunotherapies in the US, have an RSI of 45.77.

On May 31st, 2018, Advaxis announced that it will release its financial results for the six months ended April 30th, 2018 on June 07th, 2018. Senior management will host a conference call that same day to review the results and provide a business update. The conference call and live audio webcast will begin at 11:00 a.m. ET. Are you already registered with Wall St. Equities? Do so now for free, and get the report on ADXS at:

www.wallstequities.com/registration/?symbol=ADXS

Adverum Biotechnologies

Menlo Park, California headquartered Adverum Biotechnologies Inc.’s stock jumped 6.98%, finishing yesterday’s session at $6.90 with a total trading volume of 730,343 shares. The Company’s shares have surged 22.12% in the last month and 160.38% over the past year. The stock is trading above its 50-day and 200-day moving averages by 13.96% and 44.24%, respectively. Additionally, shares of Adverum Biotechnologies, which engages in developing gene therapy product candidates that target serious rare and ocular diseases, have an RSI of 67.44.

On June 04th, 2018, Adverum Biotechnologies announced that Leone Patterson, interim President and CEO, will present at the Jefferies Global Healthcare Conference on June 08th, 2018, from 12:30 p.m. ET to 12:55 p.m. ET in New York. A live and replay audio webcast of the presentation will be available on the Company’s investors website. Aspiring Member, please take a moment to register below for your free research report on ADVM at:

www.wallstequities.com/registration/?symbol=ADVM

Wall St. Equities:

Wall St. Equities (WSE) produces regular sponsored and non-sponsored reports, articles, stock market blogs, and popular investment newsletters covering equities listed on NYSE and NASDAQ and micro-cap stocks. WSE has two distinct and independent departments. One department produces non-sponsored analyst certified content generally in the form of press releases, articles and reports covering equities listed on NYSE and NASDAQ and the other produces sponsored content (in most cases not reviewed by a registered analyst), which typically consists of compensated investment newsletters, articles and reports covering listed stocks and micro-caps. Such sponsored content is outside the scope of procedures detailed below.

WSE has not been compensated; directly or indirectly; for producing or publishing this document.

PRESS RELEASE PROCEDURES:

The non-sponsored content contained herein has been prepared by a writer (the “Author”) and is fact checked and reviewed by a third-party research service company (the “Reviewer”) represented by a credentialed financial analyst [for further information on analyst credentials, please email info@wallstequities.com. Rohit Tuli, a CFA® charterholder (the “Sponsor”), provides necessary guidance in preparing the document templates. The Reviewer has reviewed and revised the content, as necessary, based on publicly available information which is believed to be reliable. Content is researched, written and reviewed on a reasonable-effort basis. The Reviewer has not performed any independent investigations or forensic audits to validate the information herein. The Reviewer has only independently reviewed the information provided by the Author according to the procedures outlined by WSE. WSE is not entitled to veto or interfere in the application of such procedures by the third-party research service company to the articles, documents or reports, as the case may be. Unless otherwise noted, any content outside of this document has no association with the Author or the Reviewer in any way.

NO WARRANTY

WSE, the Author, and the Reviewer are not responsible for any error which may be occasioned at the time of printing of this document or any error, mistake or shortcoming. No liability is accepted whatsoever for any direct, indirect or consequential loss arising from the use of this document. WSE, the Author, and the Reviewer expressly disclaim any fiduciary responsibility or liability for any consequences, financial or otherwise arising from any reliance placed on the information in this document. Additionally, WSE, the Author, and the Reviewer do not (1) guarantee the accuracy, timeliness, completeness or correct sequencing of the information, or (2) warrant any results from use of the information. The included information is subject to change without notice.

NOT AN OFFERING

This document is not intended as an offering, recommendation, or a solicitation of an offer to buy or sell the securities mentioned or discussed, and is to be used for informational purposes only. Please read all associated disclosures and disclaimers in full before investing. Neither WSE nor any party affiliated with us is a registered investment adviser or broker-dealer with any agency or in any jurisdiction whatsoever. To download our report(s), read our disclosures, or for more information, visit https://wallstequities.com/legal-disclaimer/

CONTACT

For any questions, inquiries, or comments reach out to us directly. If you’re a company, we are covering and wish to no longer feature on our coverage list contact us via email and/or phone between 09:30 EDT to 16:00 EDT from Monday to Friday at:

Email: info@wallstequities.com
Phone number: 21 32 044 483
Office Address: 1 Scotts Road #24-10, Shaw Center Singapore 228

CFA® and Chartered Financial Analyst® are registered trademarks owned by CFA Institute.

SOURCE: Wall St. Equities

ReleaseID: 501989